Sopherion Therapeutics, LLC
Therapeutic for front line breast cancer, innovative, yet well characterized medication, strong patent protection, late stage of development, large US market.
- Zoticon identifies North American rights acquisition candidate, Myocet, which at the time was enrolling patients in a phase III clinical trial in conjunction with Herceptin. The Company was backed by top tiered venture capital investors. The drug is marketed in Europe by Teva. A successful US trial will greatly expand the market Worldwide.
- Zoticon executes licensing deal giving the VC backed Company deal terms that exceeded management’s expectations and provided a framework for a $50 million dollar investment necessary to complete the phase III clinical trial.
- Zoticon assists Company in making key changes in trial design allowing Company to complete trial at half the cost and half the time.
- Zoticon assists in writing new patents which issue and extend protection for an additional 20 years.
- Company completes Phase III trial.
- Trial results were mixed: some of the endpoints were not met, but overall survival (OS) was better in the cohort that received the drug. In addition, the drug had a clear safety profile. A confirmatory trial is now being planned.
Zoticon does largest private financing of 2008 according to Bioworld.
